Clinical Trials Directory

Trials / Unknown

UnknownNCT02907606

Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study

Status
Unknown
Phase
Study type
Observational
Enrollment
45 (estimated)
Sponsor
Peking University People's Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This study will evaluate the feasibility and effectiveness of urinary ctDNA detection and dynamic monitoring during treatment of NSCLC patients prospectively,by collecting and detecting tumor tissues, peripheral blood samples and urine samples of NSCLC patients.

Detailed description

Liquid biopsy, specifically through the assessment of circulating tumor DNA(ctDNA) from peripheral blood, has shown great promise in lung cancer diagnosis and therapeutic monitoring. Urinary samples are completely non-invasive and easily obtainable compared to blood and tissue extraction. To date, only a limited number of published studies have examined the feasibility of ctDNA detection from urine. This study will collect tumor tissues, pretreatment peripheral blood samples and urine samples from different TNM stages of NSCLC patients, and detect EGFR gene mutations in paired samples.

Conditions

Timeline

Start date
2016-09-01
Primary completion
2017-06-01
Completion
2020-08-01
First posted
2016-09-20
Last updated
2016-09-20

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02907606. Inclusion in this directory is not an endorsement.